Early Treatment With Copaxone Benefits MS Patients, Reports New Data
Teva announced new data on the safety and efficacy of Copaxone (glatiramer acetate injection) 40mg/mL in patients with relapsing forms of multiple sclerosis (MS). The findings were presented at the 67th American Academy of Neurology's (AAN) Annual Meeting in Washington, D.C.
In the 36-month placebo-controlled and open-label extension phases of the Glatiramer Acetate Low-frequency Administration (GALA) study, outcomes of early start (ES) patients (n=834) who received three-times-a-week Copaxone 40mg/mL for 36 months were compared to delayed start (DS) patients (n=419) who initiated Copaxone after the 12-month placebo-controlled phase of the trial. The adjusted mean annualized relapse rate was significantly lower for the ES patients over 36 months (0.23 vs. 0.30, risk ratio [RR]=0.770; P=0.0052) and early treatment was associated with a sustained reduction in lesion activity and the evolution of active lesions to chronic black holes.
Copaxone is indicated to reduce the frequency of relapses in patients with relapsing-remitting MS, including those who have experienced a first clinical episode and have MRI features consistent with MS.
For more information call (800) 221-4026 or visit TevaUSA.com.